StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Axsome Therapeutics's total assets was $761.45M at Jun 30, 2026. For fiscal 2025 it was $689.81M, up 21.3% from the year before. Over ten years it grew 30.3% a year on average. The highest annual figure on record is $689.81M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$689.81M+21.3%
FY2024Dec 31, 2024$568.50M-3.4%
FY2023Dec 31, 2023$588.24M+77.5%
FY2022Dec 31, 2022$331.48M+277.6%
FY2021Dec 31, 2021$87.79M-52.8%
FY2020Dec 31, 2020$186.13M-15.6%
FY2019Dec 31, 2019$220.55M+1334.1%
FY2018Dec 31, 2018$15.38M-56.7%
FY2017Dec 31, 2017$35.56M-7.0%
FY2016Dec 31, 2016$38.21M-22.1%
FY2015Dec 31, 2015$49.08M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$761.45M+19.0%
Q1 FY2026Mar 31, 2026$713.61M+19.6%
Q4 FY2025Dec 31, 2025$689.81M+21.3%
Q3 FY2025Sep 30, 2025$669.25M+19.2%
Q2 FY2025Jun 30, 2025$639.79M+16.7%
Q1 FY2025Mar 31, 2025$596.67M+9.3%
Q4 FY2024Dec 31, 2024$568.50M-3.4%
Q3 FY2024Sep 30, 2024$561.46M-6.6%
Q2 FY2024Jun 30, 2024$548.23M-10.4%
Q1 FY2024Mar 31, 2024$545.73M+40.2%
Q4 FY2023Dec 31, 2023$588.24M+77.5%
Q3 FY2023Sep 30, 2023$600.86M+77.3%
Q2 FY2023Jun 30, 2023$611.64M+238.7%
Q1 FY2023Mar 31, 2023$389.18M+339.5%
Q4 FY2022Dec 31, 2022$331.48M+277.6%
Q3 FY2022Sep 30, 2022$338.96M+190.7%
Q2 FY2022Jun 30, 2022$180.56M+26.0%
Q1 FY2022Mar 31, 2022$88.56M-46.9%
Q4 FY2021Dec 31, 2021$87.79M-52.8%
Q3 FY2021Sep 30, 2021$116.60M-42.7%
Q2 FY2021Jun 30, 2021$143.26M-25.0%
Q1 FY2021Mar 31, 2021$166.90M-15.6%
Q4 FY2020Dec 31, 2020$186.13M-15.6%
Q3 FY2020Sep 30, 2020$203.63M+358.2%
Q2 FY2020Jun 30, 2020$190.99M+248.7%
Q1 FY2020Mar 31, 2020$197.80M+350.6%
Q4 FY2019Dec 31, 2019$220.55M+1334.1%
Q3 FY2019Sep 30, 2019$44.44M+175.6%
Q2 FY2019Jun 30, 2019$54.78M+152.1%
Q1 FY2019Mar 31, 2019$43.90M+57.1%
Q4 FY2018Dec 31, 2018$15.38M-56.7%
Q3 FY2018Sep 30, 2018$16.13M-50.6%
Q2 FY2018Jun 30, 2018$21.73M-44.4%
Q1 FY2018Mar 31, 2018$27.94M-39.8%
Q4 FY2017Dec 31, 2017$35.56M-7.0%
Q3 FY2017Sep 30, 2017$32.62M-6.6%
Q2 FY2017Jun 30, 2017$39.04M–
Q1 FY2017Mar 31, 2017$46.41M–
Q4 FY2016Dec 31, 2016$38.21M–
Q3 FY2016Sep 30, 2016$34.92M–

More Axsome Therapeutics figures

See a number that looks wrong?